

Resource Summary Report

Generated by [dkNET](#) on Aug 6, 2026

PerCP/Cyanine5.5 anti-human CD3

RRID:AB_10640736

Type: Antibody

Proper Citation

BioLegend Cat# 344808, RRID:AB_10640736

Antibody Information

URL: http://antibodyregistry.org/AB_10640736

Proper Citation: BioLegend Cat# 344808, RRID:AB_10640736

Target Antigen: CD3

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PerCP/Cyanine5.5 anti-human CD3

Description: This monoclonal targets CD3

Target Organism: human

Clone ID: Clone SK7

Antibody ID: AB_10640736

Vendor: BioLegend

Catalog Number: 344808

Alternative Catalog Numbers: 344807

Record Creation Time: 20250819T213049+0000

Record Last Update: 20250819T231204+0000

Ratings and Alerts

No rating or validation information has been found for PerCP/Cyanine5.5 anti-human CD3.

No alerts have been found for PerCP/Cyanine5.5 anti-human CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 12 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#).

Hernández-Blanco C, et al. (2025) The phase I RELEASE clinical trial to evaluate the safety of NK cells in COVID-19. *iScience*, 28(2), 111698.

Benton A, et al. (2025) Mutant KRAS peptide targeted CAR-T cells engineered for cancer therapy. *Cancer cell*, 43(7), 1365.

Hopkins G, et al. (2024) Lower Humoral and Cellular Immunity Following Asymptomatic SARS-CoV-2 Infection Compared to Symptomatic Infection in Education (The ACE Cohort). *Journal of clinical immunology*, 44(6), 147.

Moura DS, et al. (2024) Predictive and Dynamic Signature for Antiangiogenics in Combination with a PD1 Inhibitor in Soft-Tissue Sarcoma: Correlative Studies Linked to the IMMUNOSARC Trial. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(22), 5192.

Nellore A, et al. (2023) A transcriptionally distinct subset of influenza-specific effector memory B cells predicts long-lived antibody responses to vaccination in humans. *Immunity*, 56(4), 847.

Kastenschmidt JM, et al. (2023) Influenza vaccine format mediates distinct cellular and antibody responses in human immune organoids. *Immunity*, 56(8), 1910.

Baerends EAM, et al. (2023) SARS-CoV-2 vaccine-induced antibodies protect against Omicron breakthrough infection. *iScience*, 26(9), 107621.

Tobin RP, et al. (2023) Targeting MDSC Differentiation Using ATRA: A Phase I/II Clinical Trial Combining Pembrolizumab and All-Trans Retinoic Acid for Metastatic Melanoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 29(7), 1209.

Park JA, et al. (2023) Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody. *Journal for immunotherapy of cancer*, 11(3).

Orrantia A, et al. (2022) In vivo expansion of a CD9+ decidual-like NK cell subset following autologous hematopoietic stem cell transplantation. *iScience*, 25(10), 105235.

Guo C, et al. (2022) Single-cell transcriptome profiling and chromatin accessibility reveal an exhausted regulatory CD4⁺ T cell subset in systemic lupus erythematosus. *Cell reports*, 41(6), 111606.

Chabi S, et al. (2019) Hypoxia Regulates Lymphoid Development of Human Hematopoietic Progenitors. *Cell reports*, 29(8), 2307.